These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1627753)

  • 1. A pilot study to assess the ability of an orally available selective thromboxane synthase inhibitor to improve renal function in cyclosporine-treated renal transplant recipients.
    Weir MR; Klassen DK; Burdick JF
    J Am Soc Nephrol; 1992 Feb; 2(8):1285-90. PubMed ID: 1627753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity.
    Smith SR; Kubacki VB; Rakhit A; Martin LL; Schaffer AV; Jasani MK; Hefty DJ; Johnston T; Cannon C; Bennett WM
    Transplantation; 1993 Dec; 56(6):1422-6. PubMed ID: 8279014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary observations of the acute effects of selective serum thromboxane inhibition and angiotensin converting enzyme inhibition on blood pressure and renal hemodynamics in hypertensive humans.
    Weir MR; Klassen DK; Hoover N; Douglas FL
    J Clin Pharmacol; 1989 Dec; 29(12):1108-16. PubMed ID: 2693500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity.
    Smith SR; Creech EA; Schaffer AV; Martin LL; Rakhit A; Douglas FL; Klotman PE; Coffman TM
    Kidney Int; 1992 Jan; 41(1):199-205. PubMed ID: 1593856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion.
    Ruggenenti P; Perico N; Mosconi L; Gaspari F; Benigni A; Amuchastegui CS; Bruzzi I; Remuzzi G
    Kidney Int; 1993 Mar; 43(3):706-11. PubMed ID: 8455370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide?
    Gossmann J; Radounikli A; Bernemann A; Schellinski O; Raab HP; Bickeböller R; Scheuermann EH
    Kidney Blood Press Res; 2001; 24(2):111-5. PubMed ID: 11435743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal hemodynamics in renal transplant recipients. The role of reduced kidney mass and cyclosporine administration.
    Pluvio C; DePascale E; Pluvio M; Carone M; Giordano M; Luzi L; Sabella F; Castellino P
    Transplantation; 1996 Mar; 61(5):733-8. PubMed ID: 8607176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes.
    Hannedouche TP; Natov S; Boitard C; Lacour B; Grünfeld JP
    Nephrol Dial Transplant; 1996 Apr; 11(4):673-8. PubMed ID: 8671857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The protective effects of the thromboxane synthetase inhibitor Dazmegrel on nephrotoxicity in cyclosporine-treated rats.
    Gladue RP; Newborg MF
    Transplantation; 1991 Nov; 52(5):837-41. PubMed ID: 1949170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The reversal of experimental cyclosporin A nephrotoxicity by thromboxane synthetase inhibition.
    Grieve EM; Hawksworth GM; Simpson JG; Whiting PH
    Biochem Pharmacol; 1993 Mar; 45(6):1351-4. PubMed ID: 8466554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy.
    Kontessis PS; Jones SL; Barrow SE; Stratton PD; Alessandrini P; De Cosmo S; Ritter JM; Viberti GC
    J Lab Clin Med; 1993 Mar; 121(3):415-23. PubMed ID: 8445289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation.
    Textor SC; Burnett JC; Romero JC; Canzanello VJ; Taler SJ; Wiesner R; Porayko M; Krom R; Gores G; Hay E
    Kidney Int; 1995 May; 47(5):1426-33. PubMed ID: 7543625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the thromboxane synthesis inhibitor CGS-12970 on experimental acute renal allograft rejection.
    Mangino MJ; Brunt EM; Von Doersten P; Anderson CB
    J Pharmacol Exp Ther; 1989 Jan; 248(1):23-8. PubMed ID: 2643702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of chronic ciclosporin nephrotoxicity by thromboxane synthase inhibition with OKY-046.
    Kim YJ; Park YH; Moon HK
    Kidney Blood Press Res; 1997; 20(1):38-43. PubMed ID: 9192909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation.
    Madsen JK; Sørensen SS; Hansen HE; Pedersen EB
    Nephrol Dial Transplant; 1998 Sep; 13(9):2327-34. PubMed ID: 9761517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A.
    Branten AJ; Hilbrands LB; van Hamersvelt HW; Koene RA; Huysmans FT
    Nephrol Dial Transplant; 1998 Feb; 13(2):423-6. PubMed ID: 9509456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production of healthy humans.
    Weir MR; Klassen DK; Shen SY; Sullivan D; Buddemeyer EU; Handwerger BS
    Transplantation; 1990 Jan; 49(1):41-7. PubMed ID: 2301025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients.
    Chouinard ML; Martin LL; Coffman T; Hamilton BH; Linberg LF; Pamidi A; Simke JP; Rakhit A
    Clin Pharmacol Ther; 1992 Dec; 52(6):597-604. PubMed ID: 1458769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal hemodynamics, urinary eicosanoids, and endothelin after liver transplantation.
    Textor SC; Wilson DJ; Lerman A; Romero JC; Burnett JC; Wiesner R; Dickson ER; Krom RA
    Transplantation; 1992 Jul; 54(1):74-80. PubMed ID: 1631948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.